DarioHealth reports 6% revenue growth as AI platform expands

DarioHealth reported a 6% year-over-year increase in third quarter 2026 revenue to $5.3 million, while operating expenses fell 10%. The healthcare technology company also highlighted new health plan agreements, multi-condition products and wider deployment of its DarioIQ AI system.
- Third quarter revenue rose 6% year-over-year to $5.3 million.
- Operating expenses declined 10% and operating loss improved 15% year-over-year.
- Dario signed a New Jersey health plan covering approximately 1.5 million lives.
- DarioIQ™ is designed to predict disengagement and trigger targeted interventions.
- Dario expects revenue acceleration at the end of 2026 and into 2027.
Revenue increased as operating costs declined
DarioHealth said revenue rose from $5.0 million in the third quarter of 2025 to $5.3 million in the latest quarter, which ended September 30, 2026. Revenue also increased 3% sequentially from $5.2 million in the second quarter.
The year-over-year growth was primarily driven by direct-to-consumer sales, which increased approximately 48%. Business-to-business and B2B2C revenue declined compared with 2025, partly because several legacy Twill contracts were not renewed, although channel partner growth provided an offset.
Gross profit increased approximately 4% year-over-year to $3.1 million. GAAP gross margin was 59%, compared with 60% a year earlier, while non-GAAP B2B2C gross margin remained approximately 80% for the 11th consecutive quarter. Operating expenses fell 10% year-over-year to $11.2 million, and operating loss improved 15% year-over-year. Cash, cash equivalents and short-term deposits totaled $31.2 million as of September 30, 2026.
Health plan deals broaden Dario's customer base
DarioHealth said it has more than 180 signed accounts across employers and health plans, with contracted and late-stage annual recurring revenue of $13.1 million. More than 80% of that figure relates to multi-condition opportunities, according to the company.
Through its Amwell channel partnership, Dario signed one of New Jersey's largest health plans, representing approximately 1.5 million covered lives. Revenue contribution is expected to begin in 2027. The company said this is the third state health plan signed through the partnership in the past 12 months.
Dario also expanded an agreement with a regional grocery retailer that has more than 200 stores and 19,000 employees. The expansion adds Dario Women™, which is expected to become available to eligible insured employees in 2027. Dario Women™ and Dario Sleep extend the company's platform into menopause, perimenopause and obstructive sleep apnea.
DarioIQ targets engagement and care integration
Dario described DarioIQ™ as a generative AI layer deployed across the organization. The system is designed to predict member disengagement and trigger targeted interventions. During the quarter, members reached early returned within one week at 1.7 times the rate of comparable members who were not reached.
Based on its results, Dario expects DarioIQ could contribute to an increase of up to approximately 14% in engagement-based B2B2C annual recurring revenue from existing customers. The company also said the system was one of several contributors to the year-over-year reduction in operating expenses.
Dario is working with a national health plan customer on a marketplace model that would combine consumer choice with payer funding and bring GLP-1 therapy delivery into the member marketplace. Chief Executive Officer Erez Raphael said payers are moving toward multi-condition platforms and therapies delivered inside managed programs. For users and health plans, the strategy could connect access to specific therapies with Dario's existing chronic condition programs, member engagement capabilities and clinical and economic evidence.


